BioVaxys Forms Second Collaboration With Ohio State University For Pan-Sarbecovirus Vaccine Research

The CEO of BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) James Passen told Proactive he has partnered with Ohio State University to further develop the company’s haptenized viral antigen platform to create a vaccine Widely reactive pan-sarbecovirus. The Vancouver-based company said this was its second SARS-CoV-2 research collaboration with the state of Ohio. Sarbecoviruses, a subset of the coronaviridae family, include the emerging variants of SARS2 Delta and Omicron. Sarbecoviruses are responsible for two pandemics in less than 20 years, including SARS-CoV-1 (SARS1) in 2003 and the current coronavirus pandemic.

Add related topics to MyProactive

Create your account: sign up and get ahead of news and events


The Company is a publisher. You understand and agree that no content posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is …

In return for the publishing services rendered by the Company on behalf of the persons named herein, including the promotion by the Company of any Content on the Site, the Company receives from this issuer annual cash …


About Hector Hedgepeth

Check Also

New study challenges widely held beliefs about Alzheimer’s disease

A new study challenges the dogma behind drug trials for Alzheimer’s disease. The study found …